1. Introduction {#sec1-nutrients-11-01954}
===============

Colorectal cancer (CRC) is the second most common cancer in men and women combined, with approximately 1.4 million new cases diagnosed in 2012 worldwide \[[@B1-nutrients-11-01954]\]. There is compelling observational evidence that low circulating vitamin D concentrations are associated with increased risk of incident CRC \[[@B2-nutrients-11-01954],[@B3-nutrients-11-01954]\]. However, other human evidence is less convincing. A few Mendelian randomization (MR) studies did not support an association between vitamin D genetic score and CRC risk, but the genetic contribution to 25(OH)D is relatively small (7.5% as estimated based on genome-wide association studies (GWAS) on common SNPs \[[@B4-nutrients-11-01954]\]), possibly explaining the null findings \[[@B5-nutrients-11-01954],[@B6-nutrients-11-01954]\]. Also, the relatively few randomized clinical trials (RCTs) of vitamin D supplementation and colorectal neoplasms have not shown statistically significant effects, but sample size, duration and timing of supplementation, issues with compliance and choice of study population, and the limited range of vitamin D exposures assessed may have contributed to the null results \[[@B7-nutrients-11-01954],[@B8-nutrients-11-01954],[@B9-nutrients-11-01954]\]. Finally, the benefits from vitamin D supplementation for the prevention of colorectal neoplasms may vary according to genetic variation in the vitamin D-related genes (e.g., vitamin D receptor (*VDR*) \[[@B10-nutrients-11-01954]\]).

Anti-neoplastic effects of vitamin D on colorectal tissue are also supported by the fact that the normal colorectal epithelium expresses the vitamin D receptor (VDR) and vitamin D metabolizing enzymes (CYP27B1 and CYP24A1) and, therefore, can locally produce and degrade the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)~2~D), from 25-hydroxyvitamin D (25(OH)D) \[[@B11-nutrients-11-01954],[@B12-nutrients-11-01954],[@B13-nutrients-11-01954]\]. In the colorectum, the active metabolite of vitamin D, 1,25(OH)~2~D, exerts its anti-neoplastic effects by genomic (mediated by the VDR) and non-genomic mechanisms \[[@B14-nutrients-11-01954]\], including the regulation of over 200 vitamin D-responsive genes and rapid activation of intracellular signaling pathways, resulting in modulation of the cell cycle, bile acid degradation, immune response, growth factor signaling, and anti-inflammation \[[@B15-nutrients-11-01954]\].

Observational and RCT data suggest a potential vitamin D-colorectal neoplasms risk association is modified by polymorphisms in the vitamin D receptor (VDR) \[[@B10-nutrients-11-01954],[@B16-nutrients-11-01954],[@B17-nutrients-11-01954]\] and the vitamin D-binding protein gene (GC) \[[@B18-nutrients-11-01954]\]; however, only a few single nucleotide polymorphisms (SNPs) and a limited number of related pathways were considered. Novel evidence highlights a wide array of VDR binding sites across the human genome \[[@B19-nutrients-11-01954]\], and multiple pathways related to vitamin D effects \[[@B20-nutrients-11-01954]\]. Thus, it is plausible that the vitamin D--CRC risk association may be modulated by variation in a broad array of genes related to vitamin D metabolism (e.g. absorption, endogenous synthesis, transport, activation, and deactivation) and action (including transcriptional activity/post-transcriptional effects). All of these genes are polymorphic, but no studies to date have comprehensively investigated their individual and collective associations with CRC risk or circulating vitamin D levels. In consideration of these points, we investigated whether variation in genes related to vitamin D metabolism and transcriptional activity is related to circulating blood vitamin D levels, and whether genetic variation at the SNP, pathway and gene level, alone and in combination with circulating vitamin D levels, is associated with CRC risk in a large Western European prospective cohort study.

2. Materials and Methods {#sec2-nutrients-11-01954}
========================

2.1. Study Population {#sec2dot1-nutrients-11-01954}
---------------------

We used a case-control design nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, a large prospective study with over 520,000 men and women aged 35--70 years enrolled from 23 centers in 10 Western European countries (Denmark, France, Greece, Germany, Italy, the Netherlands, Norway, Spain, Sweden, and United Kingdom). The methods of the EPIC study have been described in detail elsewhere \[[@B21-nutrients-11-01954],[@B22-nutrients-11-01954]\]. Individuals who were eligible for the study were selected from the general population of a specific geographical area, town, or province. Exceptions included the French sub-cohort, which is based on members of the health insurance system or state-school employees, and the Utrecht (Netherlands) sub-cohort, which is based on women who underwent screening for breast cancer. Between 1992 and 1998, standardized lifestyle and personal history information, anthropometrics, and blood samples were collected from most participants at recruitment. Diet over the previous 1 year was measured at baseline by validated country-specific dietary questionnaires developed to ensure high compliance and better measures of local dietary habits \[[@B21-nutrients-11-01954]\]. Blood samples were stored at the International Agency for Research on Cancer (Lyon, France; −196 °C, in liquid nitrogen) for all countries except Denmark (−150 °C, in nitrogen vapor) and Sweden (in −80 °C freezers). The EPIC study was approved by the Ethical Review Board of the International Agency for Research on Cancer (IARC) and the Institutional Review Board of each participating EPIC center. Written consent was obtained from all EPIC participants at enrolment into the study.

2.2. Cancer Incidence and Vital Status Follow-Up {#sec2dot2-nutrients-11-01954}
------------------------------------------------

Cancer incidence was determined through record linkages with regional cancer registries (Denmark/Italy/the Netherlands/Norway/Spain/Sweden/United Kingdom; complete up to December 2006) or via a combination of methods, including the use of health insurance records, contacts with cancer and pathology registries, and active follow-up through study subjects and their next-of-kin (France/Germany/Naples/Greece; complete up to June 2010).

Vital status follow-up (98.5% complete) was collected by record linkage with regional and/or national mortality registries in all countries except France, Germany, and Greece, where data are collected through an active follow-up. Censoring dates for complete follow-up were between June 2005 and June 2009 in Denmark, the Netherlands, Spain, the United Kingdom, Sweden, Norway, and Italy. In Germany, Greece, and France follow-up was based on a combination of methods, including health insurance records, cancer and pathology registries, and active follow-up through study subjects and their next-of-kin. In these centers, the end of follow-up was defined as the last known date of contact, or the date of death whichever came first. The last update of endpoint information occurred between December 2007 and December 2009.

2.3. Nested Case-Control Design and Participant Selection {#sec2dot3-nutrients-11-01954}
---------------------------------------------------------

### 2.3.1. Case Ascertainment and Selection {#sec2dot3dot1-nutrients-11-01954}

CRC cases were selected among participants who developed colon (C18.0--C18.7, according to the ICD--10), rectum (C19--C20), and overlapping/unspecified origin tumors (C18.8 and C18.9). Cancers of the anus were excluded. CRC is defined as the combination of the colon and rectal cancers.

A total of 1420 first-time previously cancer-free colorectal cancer cases (colon cancer = 900; rectal cancer = 520) were identified. Cases were not selected from Norway (blood samples only recently collected; few colorectal cancers diagnosed after blood donation) and the Malmö center of Sweden. The number of cases for gene-environment analyses was 1176 because of missing, previously collected 25(OH)D measurements \[[@B23-nutrients-11-01954]\] (France = 6, Italy = 49, Spain = 30, UK = 27, The Netherlands = 8, Greece = 18, Germany = 21, and Sweden = 16).

### 2.3.2. Control Selection {#sec2dot3dot2-nutrients-11-01954}

Controls were selected (1:1) by incidence density sampling from all cohort members alive and not having a reported cancer at the time of diagnosis of the cases and were matched by age (±6 months at recruitment), sex, study center, time of the day at blood collection, and fasting status at the time of blood collection (less than three hours, three to six hours, and more than six hours). Women were further matched by menopausal status (pre-/post-/peri-menopausal, and unknown) and for pre-menopausal women, phase of menstrual cycle at time of blood collection and usage of postmenopausal hormone therapy at time of blood collection (yes/no, regardless of menopausal status). The additional matching criteria for women were required for other studies that were being carried out using the same matched case-control sets. One control sample failed the genotyping and was not included in the analysis, resulting in a total of 1419 controls. The number of controls for analyses involving 25(OH)D was 764 because of missing or unobtainable, previously collected 25(OH)D measurements \[[@B23-nutrients-11-01954]\] (France = 18, Italy = 69, Spain = 48, UK = 62, The Netherlands = 41, Greece = 23, Germany = 60, Sweden = 49, and Denmark = 328).

### 2.3.3. Blood 25-(OH)-Vitamin D Assessment {#sec2dot3dot3-nutrients-11-01954}

We previously measured blood concentrations of 25(OH)D using a commercially available enzyme immunoassay kit (OCTEIA 25-(OH)D Kit, Immuno Diagnostic Systems, Boldon, UK) at the Laboratory for Health Protection Research, National Institute for Public Health and the Environment, the Netherlands \[[@B23-nutrients-11-01954]\]. The kit is specific for 100% of 25-(OH)-vitamin D~3~ form and 75% of 25-(OH)-vitamin D~2~ form. The inter-assay coefficient of variation as determined with two kit control samples was minimal (5.9% at the level of 20.3 nmol/L and 5.4% at the level of 77.4 nmol/L). No significant between-day drift, time shifts, or other trends were observed and the percentage of variance attributable to batch-to-batch differences was 4.5%. For all analyses, laboratory technicians were blinded to the case-control status of the samples.

### 2.3.4. SNP Selection, Genotyping, and Quality Control {#sec2dot3dot4-nutrients-11-01954}

Genomic DNA was extracted from whole blood samples using conventional methods. We used the custom GoldenGate Universal-32 3072-plex assay kit (Illumina, CA, USA) to genotype 1716 genetic variants within the genes known and proposed to be involved in (1) vitamin D metabolism (*DHCR7, GC, CYP3A4, CYP2R1, CYP24A1, CUBN*, and *LRP2*), (2) mineral homeostasis and endocrine regulations of 1,25(OH)~2~D synthesis (*CASR, PTH, TRPV5*, and *TRPV6*), (3) vitamin D genomic effects (*VDR, RXRA, RXRB*, and *RXRG*), (4) formation of the *VDR* complex (co-activators and co-regulators *ACTL6A, ARID1A, BAZ1B, CARM1, CHAF1A, CREBBP, EP300, HDAC9, MED1, NCOA1, NCOA2, NCOA3, NCOA7, NCOR1, NCOR2, PCAF/KAT2B, PRMT1, SMARCA2, SMARCA4, SMARCC1, SMARCD1, SMARCE1, SNW1, SUPT16H, TOP2B*, and *TSC2*), and (5) vitamin D post-transcriptional response (tumor growth factor β (TGFβ)-signaling, inflammation, oxidative stress, insulin growth factor (IGF) signaling, cell cycle, and *VDR* binding sites; please see [Supplementary Table S1](#app1-nutrients-11-01954){ref-type="app"} for a complete list of genes and SNPs). The custom GoldenGate assay was designed using the Illumina online Assay Design Tool in May 2012. SNP genotype dataset for CEU population (Utah residents with Northern and Western European ancestry; HapMap Data Rel 28 Phase II + III, August 10, on NCBI B36 assembly, dbSNP b126) were loaded in the Haploview program (Broad Institute, MIT and Harvard, Cambridge, MA, USA) and SNPs with minor allele frequencies (MAFs) greater than 5% and the r^2^ linkage disequilibrium (LD) statistic of 0.8 were selected as tagging SNPs (tagSNPs). Additionally, we searched published literature for previously reported functional and regulatory SNPs in the genes of interest and included them in genotyping irrespective of MAFs or r^2^ with other SNPs. Genotyping was performed by the Genetics Laboratory at Imperial College London. After excluding 409 SNPs \[247 (14.4%) that failed genotyping, 54 (3.1%) that failed to satisfy the Hardy-Weinberg criterion ([Supplementary Table S1](#app1-nutrients-11-01954){ref-type="app"}), 98 (5.7%) missing in more than 20% of genotyped samples, and 10 (0.6%) that were monomorphic\], a total of 1307 SNPs were included in the analysis. All genotyping underwent standard quality control including concordance checks for blinded duplicates and examination of sample and SNP call rates. The lowest reproducibility frequency across 62 replicate samples was 0.98. The call rate was 95% for all samples and 95% for all SNPs.

### 2.3.5. Statistical Analysis {#sec2dot3dot5-nutrients-11-01954}

The season adjustment of 25(OH)D was carried out by the week of blood draw using the sine curve method \[[@B24-nutrients-11-01954]\]. The associations between season-adjusted 25(OH)D concentrations and genetic variants (coded as 0, 1, 2 corresponding to the number of minor alleles) were assessed among controls using linear regression models adjusted for age, sex, and center. Further adjustment for BMI, smoking status, and physical activity did not change the results substantially. We used unconditional logistic regression analysis to assess the association of individual SNPs with CRC risk, adjusting for age (continuous), sex, and study center. Results were similar when we used conditional logistic regression on 1331 complete case-matched sets. We assumed a log-additive genetic model, but also tested dominant and recessive models as the underlying genetic model for these SNPs is unknown. Further adjustment for body mass index (BMI; continuous), smoking status (never, former, current smokers, missing), physical activity (active, moderately active, moderately inactive, and inactive), alcohol intake (continuous), hormone therapy, and menopausal status did not substantially change the results, and thus these variables were not included in the final statistical model. Subgroup analyses were conducted by sex and tumor location (colon vs. rectum).

To examine the associations between genes (a combination of SNPs) and genetic pathways (a combination of genes) and CRC risk, we used the Adaptive Rank Truncated Product (ARTP) method \[[@B25-nutrients-11-01954]\] as implemented in the first step (no interaction) of the R package PIGE (<http://cran.r-project.org/web/packages/PIGE/index.html>). This method can combine associations of SNPs in each gene (or from the genes in a pathway) to provide a *P*-value at the gene or pathway level, respectively. Genetic markers in high LD (r^2^ ≥ 0.8) were excluded using the AdaJoint R package (<https://cran.r-project.org/web/packages/ARTP2>). To investigate the multiplicative interaction between the genes and genetic pathways with 25(OH)D on CRC risk, we used the modified ARTP method as implemented in the R package PIGE. The *P*-values at the SNP and the gene levels were corrected for multiple testing for the number of SNPs and for the number of genes, respectively, using the false discovery rate (Benjamini--Hochberg or BH) method \[[@B26-nutrients-11-01954]\]. Furthermore, we used traditional methods to assess potential interactions between SNPs and 25(OH)D stratifying by categories of 25(OH)D concentrations and assuming a log-additive model for genetic markers. Also, we assessed the association of 25(OH)D (per 24.96 nmoL = 10 ng/mL) with CRC risk by genotype.

All statistical tests were two-sided with *P*-values \< 0.05 considered statistically significant (SAS software, version 9.2; SAS Institute, Cary/NC; R, R Foundation for Statistical Computing, Vienna/Austria).

3. Results {#sec3-nutrients-11-01954}
==========

3.1. Baseline Characteristics of Cases and Controls {#sec3dot1-nutrients-11-01954}
---------------------------------------------------

Selected baseline characteristics of the CRC cases and matched controls are shown in [Table 1](#nutrients-11-01954-t001){ref-type="table"}. The mean age at blood donation of cases and controls was 58 years. On average, CRC cases had 4 years between blood donation and the time of diagnosis. The dataset included 520 rectal cancer cases and 900 colon cancer cases.

3.2. SNPs in the Genes Related to Vitamin D Metabolism/Transcriptional Activity and 25(OH)D {#sec3dot2-nutrients-11-01954}
-------------------------------------------------------------------------------------------

Thirty-seven SNPs in the genes related to vitamin D metabolism, formation of the *VDR* complex, and *VDR* transcriptional activity were associated with season-adjusted 25(OH)D concentrations with unadjusted *P* ≤ 0.05 among controls ([Supplementary Table S2](#app1-nutrients-11-01954){ref-type="app"}). The top 10 SNPs are shown in [Table 2](#nutrients-11-01954-t002){ref-type="table"}. Of the 37, 17 SNPs were in the genes involved in vitamin D metabolism, and 20 SNPs in the genes involved in vitamin D transcriptional activity. None of these SNPs were statistically significantly associated with 25(OH)D after BH correction. The associations of all SNPs with 25(OH)D among controls only are shown in [Supplementary Table S3A](#app1-nutrients-11-01954){ref-type="app"}, and among cases and controls combined in [Supplementary Table S3B](#app1-nutrients-11-01954){ref-type="app"}.

3.3. SNPs in the Genes Related to Vitamin D Metabolism/Function and CRC Risk {#sec3dot3-nutrients-11-01954}
----------------------------------------------------------------------------

We examined the associations between SNPs in the genes involved in vitamin D metabolism (genes = 9, SNPs = 274), mineral homeostasis and endocrine regulation of 1,25(OH)~2~D synthesis (genes = 5, SNPs = 58), vitamin D genomic effects including the *VDR* complex co-activators and co-regulators (genes = 30, SNPs = 538), and two SNPs in the intergenic regions previously associated with circulating 25(OH)D \[[@B27-nutrients-11-01954]\] and CRC risk ([Supplementary Table S4](#app1-nutrients-11-01954){ref-type="app"}). In [Table 3](#nutrients-11-01954-t003){ref-type="table"}, we show the top fifteen statistically significant SNPs associated with CRC risk defined by *P~unadjusted~* \< 0.01. However, after BH correction, none of the associations remained statistically significant (all *P~BH~* \> 0.2). The results did not differ by tumor location ([Table 3](#nutrients-11-01954-t003){ref-type="table"} and [Supplementary Table S4](#app1-nutrients-11-01954){ref-type="app"}) or sex ([Supplementary Table S5](#app1-nutrients-11-01954){ref-type="app"}).

3.4. SNPs in the Vitamin D-Responsive Genes and CRC Risk {#sec3dot4-nutrients-11-01954}
--------------------------------------------------------

We also examined the associations between 434 SNPs in the genes responsive to vitamin D, including the genes in the TGFβ and IGF signaling pathways, inflammation, oxidative stress, cell cycle, and 19 SNPs located in the *VDR* binding sites as previously published \[[@B19-nutrients-11-01954]\] ([Supplementary Table S6](#app1-nutrients-11-01954){ref-type="app"}). Twenty-five SNPs were significantly associated with CRC risk at *P* \< 0.01. However, after BH correction, none of the associations (except for *SMAD3* rs7180244; *SMAD7* rs11874392, rs12953717 and rs4939827) remained statistically significant ([Supplementary Table S7](#app1-nutrients-11-01954){ref-type="app"}). Interestingly, three SNPs (rs3197999, rs3802842, rs762421) in previously identified *VDR* binding sites were associated with CRC risk. The results did not differ by tumor location ([Supplementary Tables S6 and S7](#app1-nutrients-11-01954){ref-type="app"}) or sex ([Supplementary Table S8](#app1-nutrients-11-01954){ref-type="app"}).

3.5. Vitamin D Genes/Pathways and CRC Risk {#sec3dot5-nutrients-11-01954}
------------------------------------------

At the pathway level, the *VDR* binding sites and TGFβ signaling pathway were statistically significantly associated with CRC risk (*P* \< 0.04; [Table 4](#nutrients-11-01954-t004){ref-type="table"}). For colon cancer, in addition to the *VDR* binding sites (*P* = 0.008) and TGFβ signaling pathway (*P* = 0.0001), an association with cell cycle pathway was observed (*P* = 0.03). The TGFβ (*P* = 0.0001) and IGF (*P* = 0.007) signaling pathways, but not the *VDR* binding sites (*P* = 0.256), were statistically significantly associated with rectal cancer risk.

At the gene level, several genes (*CHAF1A, SMARCE1, SMAD7, SMAD3, BMP2*, and *C-MYC* region) were associated with CRC risk at unadjusted *P* \< 0.05. However, all of them except *SMAD7* (*P~BH~* = 0.008) and *SMAD3* (*P~BH~* = 0.008) were not statistically significant after BH correction. The *SMAD7, SMAD3, BMP2*, and *C-MYC* regions were associated with colon cancer; however, after BH correction, only *SMAD7* (*P~BH~* = 0.04) and *SMAD3* (*P~BH~* = 0.009) remained statistically significant. In addition to *SMAD7* (*P* = 0.0005) and *SMAD3* (*P* = 0.0003), several other genes or genetic regions (*CYP2R1, CHAF1A, CREBBP, IL10*, SNPs identified in genome-wide association studies (GWAS) to be associated with IGF levels, *IGFBP2/IGFBP5, IGFBP3*, and *C-MYC* region) were associated with rectal cancer. However, after BH correction, only *SMAD7* (*P* = 0.02) and *SMAD3* (*P* = 0.02) remained statistically significant.

3.6. 25. (OH)D-Gene and 25(OH)D Pathway Interactions and CRC Risk {#sec3dot6-nutrients-11-01954}
-----------------------------------------------------------------

At the pathway level, the *VDR* complex and its transcriptional co-regulators and co-activators demonstrated a potential interaction with 25(OH)D concentrations in the association with CRC risk (*P* = 0.04; [Table 4](#nutrients-11-01954-t004){ref-type="table"}). Within this pathway, the interaction *P*-values of \<0.05 were observed for *ARID1A, CARM1, CHAF1A*, and *SMARCA2*, but none were statistically significant after BH correction. Similar associations were observed for colon cancer, but not rectal cancer (*P* for interaction for the *VDR* complex and its transcriptional co-regulators and co-activators were 0.105 and 0.727, respectively).

At the gene level, the interaction *P*-values of \<0.05 were observed for *CYP27B1* and *GC* (vitamin D metabolism) and *IL10* (inflammation) for CRC and colon cancer. Also, the interaction between 25(OH)D and *IGFBP2/IGFBP5* was statistically significant for colon cancer. For rectal cancer, the interaction *P*-values of \<0.05 were observed for *CYP24A1* (vitamin D metabolism) and *BMP2* (TGF signaling). None of the gene-25(OH)D interactions were statistically significant after BH correction.

Next, we assessed the associations between 25(OH)D (per 24.96 nmol/L) with CRC risk, stratified by genotypes of SNPs in the genes that were identified in the step above as potentially modifying the association of 25(OH)D with CRC risk (*CYP27B1*, *GC*, *ARID1A, CARM1, CHAF1A*, *SMARCA2*, and *IL10;* [Supplementary Table S9](#app1-nutrients-11-01954){ref-type="app"}). Sixteen SNPs in these genes with *P* for interaction \<0.05 are presented in [Table 5](#nutrients-11-01954-t005){ref-type="table"}. None were statistically significant after BH correction. Several SNPs had a very low number of minor allele homozygotes, with no effect estimates presented in the table.

4. Discussion {#sec4-nutrients-11-01954}
=============

In this large European prospective case-control study nested within the EPIC cohort, we investigated whether genetic variation in the genes and pathways related to vitamin D metabolism and vitamin D genomic effects is associated with CRC risk, and whether these associations are modified by 25(OH)D concentrations.

We identified several genes related to vitamin D metabolism, the VDR complex, and VDR transcriptional activity associated with 25(OH)D concentrations, with an unadjusted *P* \< 0.01 before BH correction among controls. We confirmed two genes related to vitamin D metabolism, *CYP27B1* and *GC*, and one in the *VDR*, which were identified in previous GWAS studies \[[@B28-nutrients-11-01954],[@B29-nutrients-11-01954],[@B30-nutrients-11-01954],[@B31-nutrients-11-01954],[@B32-nutrients-11-01954]\]. We also identified other genes in our study including 1) two genes that encode the transcription-related factors *HDAC9* and *NCOA7*, involved in vitamin D transcriptional activity and VDR complex formation, and 2) two genes that encode the vitamin D-related transporters *LRP2* and *CUBN* \[[@B33-nutrients-11-01954],[@B34-nutrients-11-01954]\]. *LRP2*, commonly known as megalin, is responsible for the endocytosis of the 25(OH)D vitamin D binding protein complex \[[@B35-nutrients-11-01954]\]. *CUBN* is an important co-receptor in the megalin-mediated endocytic pathway and patients without functioning CUBN were found to have abnormal 25(OH)D metabolism \[[@B33-nutrients-11-01954]\].

The genes associated with circulating 25(OH)D concentrations were also associated with CRC risk at unadjusted *P* \< 0.01 before BH correction. *HDAC9* is located in a region on chromosome 7p21 \[[@B36-nutrients-11-01954]\] in which chromosomal gains were observed in primary CRC \[[@B37-nutrients-11-01954]\]. Furthermore, HDAC9 has been observed via chromatin immunoprecipitation (ChIP) assay in human osteosarcoma tissues to suppress p53 transcription and, thereby, promote cell proliferation \[[@B38-nutrients-11-01954]\]. An association of *CUBN* with CRC was previously reported in a meta-analysis of six GWAS studies \[[@B39-nutrients-11-01954]\], while no studies have investigated a possible association of *LRP2* with CRC. *LRP2* is expressed in multiple epithelial cell lines, including colon \[[@B35-nutrients-11-01954],[@B40-nutrients-11-01954]\] and is often co-expressed with *CUBN* \[[@B34-nutrients-11-01954]\]. Additionally, there are no previous GWAS regarding CRC and *NCOA7*, although Higginbotham et al., found statistically significant associations of *NCOA7* gene variants with reduced breast cancer risk across three different study cohorts \[[@B41-nutrients-11-01954]\]. The *NCOA7* SNPs identified in our study, however, differed from those identified by Higginbotham suggesting a possible novel CRC susceptibility locus.

Three *VDR* binding site SNPs were associated with CRC risk in our study population, but the associations were not statistically significant after BH correction. We a priori selected these *VDR* binding sites for genotyping based on the results of a previous study that used ChIP followed by DNA sequencing to identify 2776 *VDR* binding sites in lymphoblastoid cell lines treated with calcitriol, an active form of vitamin D \[[@B19-nutrients-11-01954]\]. The study found a statistically significant 4-fold increase in the enrichment of *VDR* binding sites located in genes associated with CRC, and a 3.5-fold increase in enrichment located in genes associated with Crohn's disease \[[@B19-nutrients-11-01954]\]. Our findings suggest that genetic variation in these *VDR* binding sites, upregulated in response to treatment with vitamin D and relevant to colorectal carcinogenesis and inflammatory bowel diseases, may be associated with CRC risk.

TGFβ has an important role in the regulation of cell proliferation, differentiation, migration and apoptosis \[[@B42-nutrients-11-01954]\], and may be modulated by vitamin D \[[@B43-nutrients-11-01954]\]. *SMAD7* and *SMAD3*, in the TGFβ signaling pathway, were statistically significantly associated with CRC risk after BH correction for multiple testing. *SMAD7* SNPs were previously identified to be associated with CRC risk in several different populations \[[@B44-nutrients-11-01954],[@B45-nutrients-11-01954],[@B46-nutrients-11-01954]\] as well as in a meta-analysis of 2906 cases and 3416 controls from four previous GWAS studies \[[@B47-nutrients-11-01954]\]. SMAD7 is transcriptionally induced by cytokines from the TGFβ family and regulates the TGFβ signaling pathway via a negative feedback loop \[[@B42-nutrients-11-01954]\]; therefore, the overexpression of SMAD7 inhibits the pathway and its associated anti-neoplastic effects \[[@B42-nutrients-11-01954]\]. The active form of vitamin D was shown to inhibit SMAD7 in experimental models \[[@B48-nutrients-11-01954]\]. The role of *SMAD3* in the development of CRC is less understood and somatic tumor mutations in this gene have been observed in only 4.3% of CRC cases \[[@B49-nutrients-11-01954]\]. SMAD3 has been identified to interact with *VDR* and mediate a cross-talk between TGFβ and vitamin D signaling pathways \[[@B50-nutrients-11-01954]\]. An animal model found that *SMAD3* may also play an important role in the TGFβ response to inflammation and bacteria-induced colon carcinogenesis \[[@B51-nutrients-11-01954]\]. Inflammation is further associated with CRC risk in our study as indicated by the interaction between circulating 25(OH)D concentrations, which has anti-inflammatory properties \[[@B52-nutrients-11-01954],[@B53-nutrients-11-01954]\], and genetic variation in the *IL10* gene encoding anti-inflammatory cytokine interleukin (IL)-10 involved in immune response to pathogens \[[@B54-nutrients-11-01954]\]. The induction of IL-10 is mediated by 1,25(OH)~2~D and is repressed with SMAD3 inhibition \[[@B48-nutrients-11-01954]\].

Chromosome *8q24* polymorphisms in the cell cycle pathway were previously identified to be strongly associated with CRC risk \[[@B47-nutrients-11-01954],[@B55-nutrients-11-01954],[@B56-nutrients-11-01954]\]. However, they were not statistically significant after BH correction. Although the *8q24* region is described as a gene desert, it is closely located to the region encoding *c-MYC* oncogene \[[@B57-nutrients-11-01954]\]. *C-MYC* controls processes related to cell growth regulation, metabolism and proliferation and is not only activated by numerous oncogenic pathways but also stimulates metabolic changes which can lead to malignant transformation \[[@B58-nutrients-11-01954]\]. Multiple studies have identified long-range physical interaction of the *8q24* region with *c-MYC* via enhancer elements and chromatin loops \[[@B57-nutrients-11-01954],[@B59-nutrients-11-01954],[@B60-nutrients-11-01954]\]. In an experimental study, 1,25(OH)~2~D and the *VDR* were shown to affect the c-*MYC/MXD1* pathway leading to inhibition of c-MYC protein expression \[[@B61-nutrients-11-01954]\]. Using *8q24* SNPs as a proxy, our results confirm an association between *c-MYC* and CRC risk, but do not indicate a potential modification by 25(OH)D despite a previously reported possible interaction for fatal prostate cancer risk \[[@B62-nutrients-11-01954]\].

The IGF signaling pathway plays a key role in cell growth \[[@B63-nutrients-11-01954]\]. In our study, IGF-related genetic variation was associated with rectal cancer risk at the pathway level as well as for several individual genes before BH correction. Contrary to our results, IGF genetic variants \[[@B64-nutrients-11-01954],[@B65-nutrients-11-01954]\] in addition to high circulating IGF peptides \[[@B66-nutrients-11-01954]\] have been previously associated more strongly with increased colon versus rectal cancer risk.

The strengths of our study include its prospective design and high follow-up rate. The hypothesis-driven selection of pathways, genes, and SNPs, and relatively large samples size within a large cohort study allowed an extensive investigation of vitamin D--related and --responsive genetic variation and the effect modification by established biomarker of vitamin D status with CRC risk. We used the detailed data from EPIC to address potential confounding by body size and other factors; with our careful analyses suggesting no or little confounding. However, we cannot altogether discount the possibility of residual confounding nor changes in lifestyle habits between enrolment into the cohort and the eventual cancer diagnosis. Although our study was large, most interaction and stratified analyses had limited power, especially by sex and tumor location. Our power analyses ([Supplementary Table S10](#app1-nutrients-11-01954){ref-type="app"}) showed that we have sufficient power (80%) to detect the effect associations in the range of 1.17 to 1.27 for relatively common SNPs with MAF between 40 and 10%, respectively, using our full data set (n = 1419 matched case-control sets). In addition, most of our results were not statistically significant after BH correction for multiple testing. As to the selection of genes and pathways, we were limited by published literature on vitamin D at the time of genotyping, so we may have not included all vitamin D-responsive genes. Additional experimental studies are needed to understand the biological mechanisms of the identified associations.

5. Conclusions {#sec5-nutrients-11-01954}
==============

This large and comprehensive study has confirmed genetic variations in several previously identified vitamin D-related pathways associated with CRC risk in European populations, and has suggested potential new pathways related to vitamin D genomic effects and colorectal carcinogenesis.
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nutrients-11-01954-t001_Table 1

###### 

Selected baseline characteristics of incident colorectal cancer (CRC) cases and their matched controls, the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1992--2003.

  Baseline Characteristic                    Cases   Controls           
  ------------------------------------------ ------- ---------- ------- --------
  Women, N (%)                               705     (49.6)     701     (49.4)
  Mean age at blood collection, (SD) years   58.5    (7.3)      58.6    (7.3)
  Mean years of follow-up, (SD) years        4.1     (2.3)      \-\--   
  Smoking status, N (%) ^a^                                             
    Never                                    580     (40.8)     594     (41.9)
    Former                                   476     (33.5)     460     (32.4)
    Current                                  346     (24.4)     349     (24.6)
  Physical activity, N (%)                                              
    Inactive                                 202     (14.2)     183     (12.9)
    Moderately inactive                      402     (28.3)     367     (25.9)
    Moderately active                        583     (41.1)     612     (43.1)
    Active                                   130     (9.2)      148     (10.4)
  BMI, (SD) kg/m^2^                          26.8    (4.2)      26.3    (3.8)
  25-(OH)-vitamin D measurement, N (%)       1,176   (82.8)     764     (53.8)
  25-(OH)-vitamin D, mean (SD) nmol/L ^b^    58.5    (25.6)     62.0    (25.4)
  Country, N (%)                                                        
    France                                   28      (2.0)      29      (2.0)
    Italy                                    202     (14.2)     198     (14.0)
    Spain                                    146     (10.3)     141     (9.9)
    United Kingdom                           240     (16.9)     250     (17.6)
    The Netherlands                          153     (10.8)     158     (11.1)
    Greece                                   46      (3.2)      48      (3.4)
    Germany                                  179     (12.6)     169     (11.9)
    Sweden                                   88      (6.2)      86      (6.1)
    Denmark                                  338     (23.8)     340     (24.0)

^a^ Percent missing is not shown. Therefore the total percentages do not add up to 100%. ^b^ Season standardized using the sine-curve method \[[@B25-nutrients-11-01954]\].

nutrients-11-01954-t002_Table 2

###### 

Top 10 single-nucleotide polymorphisms (SNPs) in the genes related to vitamin D metabolism and transcriptional activity associated with season-adjusted 25(OH)D concentrations among controls only, the EPIC study, 1992--2003 ^a^.

  Gene ^b^    SNP          N     25(OH)D, β (95% CI)     *P*       *P~BH~* ^c^
  ----------- ------------ ----- ----------------------- --------- -------------
  *VDR*       rs2239182    742   −3.82 (−6.15, −1.49)    *0.001*   *0.949*
  *LRP2*      rs2673170    747   −4.43 (−7.27, −1.58)    *0.002*   *0.949*
  *NCOA7*     rs579477     758   −3.57 (−6.07, −1.07)    *0.005*   *0.949*
  *GC*        rs1352844    747   5.26 (1.63, 8.88)       *0.005*   *0.949*
  *GC*        rs188812     752   5.38 (1.57, 9.20)       *0.006*   *0.949*
  *GC*        rs2298849    757   4.26 (1.11, 7.41)       *0.008*   *0.949*
  *CUBN*      rs4525114    750   7.11 (1.94, 12.29)      *0.007*   *0.949*
  *CYP27B1*   rs4646536    751   3.65 (0.93, 6.37)       *0.009*   *0.949*
  *CYP27B1*   rs10877013   764   3.42 (0.73, 6.12)       *0.013*   *0.974*
  *HDAC9*     rs212669     753   −8.12 (−14.34, −1.90)   *0.011*   *0.974*

^a^ Adjusted for age at blood collection, sex, and center. ^b^ Genes related to vitamin D metabolism and transcriptional activity. ^c^ *P* after Benjamini--Hochberg (BH) multiple testing correction.

nutrients-11-01954-t003_Table 3

###### 

Associations of SNPs with CRC risk overall and by tumor location (colon vs. rectum), the EPIC study, 1992--2003.

  Gene/SNP     Genotype    Colorectal Cancer   Colon Cancer   Rectal Cancer                                                                                                   
  ------------ ----------- ------------------- -------------- ------------------- ------- ------- ----- ------------------- ------- ------- ----- ------------------- ------- -------
  *CUBN*                                                                                                                                                                      
  rs12243895   GG          702                 767            1.00 (ref)          0.009   0.569   435   1.00 (ref)          0.006   0.509   267   1.00 (ref)          0.261   0.969
               GA          551                 513            1.18 (1.00, 1.38)                   354   1.20 (1.00, 1.44)                   197   1.12 (0.90, 1.40)           
               AA          140                 104            1.48 (1.12, 1.96)                   94    1.59 (1.17, 2.16)                   46    1.34 (0.91, 1.97)           
               Additive    1393                1384           1.20 (1.07, 1.35)   0.002   0.274   883   1.24 (1.08, 1.41)   0.002   0.254   510   1.14 (0.97, 1.34)   0.106   0.824
               Dominant    1393                1384           1.22 (1.05, 1.43)   0.009   0.561   883   1.27 (1.07, 1.50)   0.007   0.571   510   1.16 (0.94, 1.43)   0.169   0.896
               Recessive   1393                1384           1.38 (1.05, 1.80)   0.020   0.898   883   1.46 (1.08, 1.97)   0.013   0.827   510   1.27 (0.88, 1.85)   0.204   0.939
  rs1801224    AA          601                 669            1.00 (ref)          0.015   0.677   359   1.00 (ref)          0.004   0.473   242   1.00 (ref)          0.517   0.998
               AC          614                 582            1.18 (1.00, 1.38)                   399   1.26 (1.05, 1.51)                   215   1.04 (0.84, 1.30)           
               CC          180                 144            1.40 (1.09, 1.80)                   120   1.52 (1.15, 2.01)                   60    1.22 (0.87, 1.73)           
               Additive    1395                1395           1.18 (1.06, 1.32)   0.004   0.374   878   1.24 (1.09, 1.41)   0.001   0.169   517   1.08 (0.93, 1.27)   0.308   0.926
               Dominant    1395                1395           1.22 (1.05, 1.42)   0.010   0.561   878   1.31 (1.10, 1.56)   0.002   0.377   517   1.07 (0.87, 1.32)   0.494   0.965
               Recessive   1395                1395           1.29 (1.02, 1.63)   0.035   0.898   878   1.35 (1.04, 1.76)   0.026   0.875   517   1.20 (0.86, 1.67)   0.276   0.986
  rs7096079    CC          275                 338            1.00 (ref)          0.023   0.677   159   1.00 (ref)          0.007   0.509   116   1.00 (ref)          0.587   0.998
               CA          654                 620            1.31 (1.08, 1.60)                   417   1.43 (1.14, 1.80)                   237   1.13 (0.87, 1.48)           
               AA          301                 305            1.22 (0.97, 1.53)                   194   1.36 (1.04, 1.77)                   107   1.03 (0.75, 1.40)           
               Additive    1230                1263           1.10 (0.99, 1.24)   0.084   0.894   770   1.16 (1.02, 1.32)   0.025   0.712   460   1.02 (0.87, 1.18)   0.841   0.996
               Dominant    1230                1263           1.28 (1.07, 1.54)   0.008   0.561   770   1.41 (1.13, 1.75)   0.002   0.377   460   1.10 (0.86, 1.41)   0.461   0.965
               Recessive   1230                1263           1.02 (0.85, 1.22)   0.861   1.000   770   1.06 (0.86, 1.31)   0.578   0.991   460   0.95 (0.73, 1.22)   0.668   0.997
  *VDR*                                                                                                                                                                       
  rs886441     AA          885                 926            1.00 (ref)          0.024   0.677   563   1.00 (ref)          0.028   0.729   322   1.00 (ref)          0.179   0.963
               AG          444                 404            1.16 (0.98, 1.36)                   273   1.12 (0.93, 1.35)                   171   1.21 (0.97, 1.52)           
               GG          57                  36             1.66 (1.08, 2.56)                   40    1.83 (1.15, 2.93)                   17    1.32 (0.73, 2.41)           
               Additive    1386                1366           1.20 (1.05, 1.38)   0.009   0.508   876   1.20 (1.03, 1.40)   0.020   0.670   510   1.19 (0.99, 1.44)   0.067   0.690
               Dominant    1386                1366           1.20 (1.02, 1.40)   0.027   0.693   876   1.18 (0.98, 1.41)   0.078   0.896   510   1.22 (0.99, 1.52)   0.067   0.750
               Recessive   1386                1366           1.59 (1.04, 2.43)   0.034   0.898   876   1.77 (1.11, 2.81)   0.016   0.827   510   1.24 (0.68, 2.25)   0.481   0.997
  *NCOA2*                                                                                                                                                                     
  rs10087049   AA          393                 472            1.00 (ref)          0.007   0.569   240   1.00 (ref)          0.003   0.448   153   1.00 (ref)          0.180   0.963
               AG          724                 665            1.32 (1.11, 1.56)                   464   1.40 (1.15, 1.71)                   260   1.17 (0.92, 1.48)           
               GG          173                 182            1.14 (0.89, 1.46)                   120   1.30 (0.98, 1.72)                   53    0.88 (0.61, 1.26)           
               Additive    1290                1319           1.12 (1.00, 1.26)   0.054   0.848   824   1.19 (1.04, 1.36)   0.010   0.596   466   1.00 (0.85, 1.17)   0.959   0.996
               Dominant    1290                1319           1.28 (1.08, 1.51)   0.004   0.469   824   1.38 (1.14, 1.67)   0.001   0.297   466   1.11 (0.88, 1.39)   0.385   0.963
  *NCOA7*                                                                                                                                                                     
  rs10223441   CC          648                 709            1.00 (ref)          0.007   0.569   399   1.00 (ref)          0.009   0.531   249   1.00 (ref)          0.153   0.939
               CG          640                 561            1.25 (1.07, 1.47)                   413   1.30 (1.09, 1.55)                   227   1.17 (0.95, 1.45)           
               GG          128                 149            0.93 (0.72, 1.21)                   84    0.98 (0.72, 1.31)                   44    0.85 (0.59, 1.23)           
               Additive    1416                1419           1.06 (0.95, 1.19)   0.277   0.921   896   1.09 (0.96, 1.24)   0.183   0.920   520   1.01 (0.87, 1.18)   0.882   0.996
               Dominant    1416                1419           1.19 (1.02, 1.38)   0.025   0.669   896   1.23 (1.04, 1.46)   0.017   0.685   520   1.10 (0.90, 1.35)   0.338   0.944
               Recessive   1416                1419           0.84 (0.65, 1.08)   0.169   0.948   896   0.86 (0.65, 1.14)   0.295   0.991   520   0.79 (0.55, 1.13)   0.202   0.939
  rs17292488   GG          594                 639            1.00 (ref)          0.004   0.569   375   1.00 (ref)          0.019   0.659   219   1.00 (ref)          0.031   0.882
               GA          657                 575            1.23 (1.05, 1.44)                   416   1.21 (1.01, 1.46)                   241   1.26 (1.01, 1.57)           
               AA          148                 185            0.86 (0.67, 1.10)                   97    0.86 (0.65, 1.13)                   51    0.85 (0.60, 1.21)           
               Additive    1399                1399           1.01 (0.90, 1.13)   0.841   0.998   888   1.00 (0.89, 1.14)   0.942   0.994   511   1.02 (0.88, 1.19)   0.802   0.996
               Dominant    1399                1399           1.14 (0.98, 1.33)   0.087   0.876   888   1.13 (0.95, 1.34)   0.174   0.944   511   1.16 (0.94, 1.43)   0.155   0.896
               Recessive   1399                1399           0.77 (0.61, 0.97)   0.028   0.898   888   0.77 (0.59, 1.01)   0.059   0.973   511   0.76 (0.54, 1.06)   0.102   0.939
  *NCOR2*                                                                                                                                                                     
  rs10846670   AA          288                 360            1.00 (ref)          0.021   0.677   169   1.00 (ref)          0.007   0.509   119   1.00 (ref)          0.676   0.998
               AG          688                 669            1.29 (1.07, 1.56)                   441   1.39 (1.12, 1.74)                   247   1.12 (0.86, 1.44)           
               GG          274                 265            1.30 (1.03, 1.64)                   177   1.42 (1.09, 1.86)                   97    1.12 (0.81, 1.53)           
               Additive    1250                1294           1.15 (1.02, 1.29)   0.020   0.663   787   1.20 (1.05, 1.37)   0.007   0.564   463   1.06 (0.91, 1.24)   0.461   0.927
               Dominant    1250                1294           1.29 (1.08, 1.55)   0.005   0.528   787   1.40 (1.13, 1.73)   0.002   0.377   463   1.12 (0.87, 1.43)   0.377   0.962
               Recessive   1250                1294           1.09 (0.90, 1.32)   0.356   0.987   787   1.13 (0.91, 1.41)   0.256   0.991   463   1.04 (0.80, 1.36)   0.777   0.997
  rs906304     GG          1032                1082           1.00 (ref)          0.010   0.569   666   1.00 (ref)          0.005   0.496   366   1.00 (ref)          0.025   0.827
               GA          359                 298            1.26 (1.06, 1.51)                   220   1.20 (0.98, 1.47)                   139   1.37 (1.08, 1.74)           
               AA          20                  32             0.66 (0.38, 1.17)                   6     0.30 (0.13, 0.74)                   14    1.36 (0.71, 2.62)           
               Additive    1411                1412           1.12 (0.96, 1.31)   0.141   0.894   892   1.02 (0.85, 1.22)   0.822   0.990   519   1.30 (1.07, 1.59)   0.010   0.514
               Dominant    1411                1412           1.21 (1.02, 1.43)   0.032   0.693   892   1.12 (0.92, 1.36)   0.268   0.954   519   1.37 (1.09, 1.73)   0.007   0.416
               Recessive   1411                1412           0.63 (0.35, 1.11)   0.106   0.931   892   0.29 (0.12, 0.70)   0.006   0.714   519   1.26 (0.66, 2.40)   0.490   0.997
  *CHAF1A*                                                                                                                                                                    
  rs243352     CC          410                 369            1.00 (ref)          0.014   0.677   250   1.00 (ref)          0.240   0.977   160   1.00 (ref)          0.003   0.453
               CA          695                 673            0.93 (0.78, 1.11)                   438   0.97 (0.79, 1.19)                   257   0.85 (0.67, 1.08)           
               AA          285                 346            0.74 (0.60, 0.91)                   190   0.82 (0.65, 1.05)                   95    0.60 (0.44, 0.80)           
               Additive    1390                1388           0.86 (0.78, 0.96)   0.006   0.417   878   0.91 (0.81, 1.03)   0.128   0.920   512   0.78 (0.67, 0.90)   0.001   0.132
               Dominant    1390                1388           0.86 (0.73, 1.02)   0.087   0.876   878   0.92 (0.76, 1.11)   0.392   0.956   512   0.76 (0.61, 0.95)   0.018   0.629
               Recessive   1390                1388           0.77 (0.65, 0.92)   0.005   0.648   878   0.84 (0.69, 1.03)   0.097   0.981   512   0.66 (0.51, 0.86)   0.002   0.729
  rs9352       AA          461                 417            1.00 (ref)          0.023   0.677   277   1.00 (ref)          0.315   0.995   184   1.00 (ref)          0.003   0.453
               AG          648                 681            0.86 (0.72, 1.02)                   413   0.92 (0.76, 1.13)                   235   0.75 (0.60, 0.95)           
               GG          254                 307            0.74 (0.60, 0.92)                   166   0.83 (0.65, 1.06)                   88    0.61 (0.46, 0.83)           
               Additive    1363                1405           0.86 (0.78, 0.96)   0.006   0.417   856   0.91 (0.81, 1.03)   0.131   0.920   507   0.78 (0.67, 0.90)   0.001   0.132
               Dominant    1363                1405           0.82 (0.70, 0.97)   0.018   0.597   856   0.89 (0.74, 1.08)   0.238   0.954   507   0.71 (0.57, 0.88)   0.002   0.243
               Recessive   1363                1405           0.81 (0.68, 0.98)   0.032   0.898   856   0.87 (0.70, 1.07)   0.192   0.991   507   0.73 (0.56, 0.95)   0.018   0.939
  *HDAC9*                                                                                                                                                                     
  rs2520361    AA          881                 841            1.00 (ref)          0.021   0.677   556   1.00 (ref)          0.161   0.960   325   1.00 (ref)          0.033   0.882
               AG          385                 395            0.92 (0.78, 1.09)                   240   0.93 (0.76, 1.13)                   145   0.91 (0.72, 1.15)           
               GG          50                  79             0.60 (0.41, 0.87)                   36    0.68 (0.45, 1.02)                   14    0.46 (0.26, 0.83)           
               Additive    1316                1315           0.85 (0.75, 0.97)   0.018   0.641   832   0.88 (0.75, 1.02)   0.086   0.920   484   0.81 (0.67, 0.98)   0.027   0.664
               Dominant    1316                1315           0.87 (0.74, 1.02)   0.089   0.876   832   0.89 (0.74, 1.07)   0.197   0.946   484   0.84 (0.67, 1.05)   0.122   0.853
               Recessive   1316                1315           0.61 (0.43, 0.88)   0.009   0.898   832   0.69 (0.46, 1.04)   0.079   0.973   484   0.48 (0.27, 0.85)   0.013   0.939
  rs4141042    AA          1028                1072           1.00 (ref)          0.007   0.569   645   1.00 (ref)          0.006   0.509   383   1.00 (ref)          0.146   0.921
               AG          366                 304            1.26 (1.06, 1.50)                   238   1.30 (1.07, 1.58)                   128   1.23 (0.97, 1.57)           
               GG          18                  31             0.60 (0.33, 1.09)                   10    0.54 (0.26, 1.12)                   8     0.71 (0.32, 1.56)           
               Additive    1412                1407           1.11 (0.95, 1.30)   0.176   0.916   893   1.13 (0.95, 1.35)   0.166   0.920   519   1.10 (0.90, 1.36)   0.346   0.926
               Dominant    1412                1407           1.20 (1.01, 1.42)   0.039   0.752   893   1.23 (1.01, 1.49)   0.035   0.806   519   1.18 (0.93, 1.49)   0.164   0.896
               Recessive   1412                1407           0.57 (0.32, 1.03)   0.062   0.916   893   0.51 (0.25, 1.05)   0.067   0.973   519   0.67 (0.30, 1.49)   0.328   0.986
  *SMARCC1*                                                                                                                                                                   
  rs3755637    GG          661                 605            1.00 (ref)          0.015   0.677   412   1.00 (ref)          0.026   0.729   249   1.00 (ref)          0.073   0.882
               GA          520                 601            0.79 (0.67, 0.93)                   322   0.78 (0.64, 0.93)                   198   0.81 (0.65, 1.02)           
               AA          132                 141            0.86 (0.66, 1.12)                   90    0.95 (0.70, 1.27)                   42    0.70 (0.48, 1.03)           
               Additive    1313                1347           0.87 (0.78, 0.98)   0.023   0.712   824   0.90 (0.79, 1.03)   0.111   0.920   489   0.83 (0.70, 0.97)   0.023   0.650
               Dominant    1313                1347           0.80 (0.69, 0.93)   0.005   0.517   824   0.81 (0.68, 0.96)   0.017   0.685   489   0.79 (0.64, 0.98)   0.030   0.679
               Recessive   1313                1347           0.96 (0.75, 1.24)   0.758   1.000   824   1.07 (0.80, 1.41)   0.659   0.991   489   0.78 (0.54, 1.12)   0.174   0.939
  *TOP2B*                                                                                                                                                                     
  rs1001647    AA          948                 884            1.00 (ref)          0.022   0.677   612   1.00 (ref)          0.011   0.531   336   1.00 (ref)          0.460   0.993
               AG          353                 415            0.79 (0.66, 0.93)                   220   0.74 (0.61, 0.90)                   133   0.87 (0.68, 1.10)           
               GG          57                  55             0.94 (0.64, 1.39)                   37    0.91 (0.59, 1.41)                   20    1.06 (0.61, 1.81)           
               Additive    1358                1354           0.86 (0.75, 0.99)   0.032   0.792   869   0.83 (0.71, 0.97)   0.017   0.650   489   0.93 (0.77, 1.13)   0.454   0.926
               Dominant    1358                1354           0.80 (0.68, 0.95)   0.009   0.561   869   0.76 (0.63, 0.92)   0.004   0.442   489   0.89 (0.71, 1.11)   0.298   0.943
               Recessive   1358                1354           1.02 (0.70, 1.49)   0.922   1.000   869   1.00 (0.65, 1.55)   0.982   0.999   489   1.11 (0.65, 1.90)   0.702   0.997

^a^ Unconditional logistic regression adjusted for age at blood collection, sex, and study center. ^b^ *P* of false discovery rate (BH; Benjamini--Hochberg) method.
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###### 

P-values of pathway- and gene-level associations with CRC risk overall and by tumor location (colon vs. rectal) and of interactions with 25(OH)D concentrations (per 24.96 nmol/L), the EPIC study, 1992--2003.

  Pathway/Gene                                                      No. of SNPs   No. of SNPs Retained After Pruning   Colorectal Cancer   Colon Cancer   Rectal Cancer                                                                                             
  ----------------------------------------------------------------- ------------- ------------------------------------ ------------------- -------------- --------------- ------- ------------ ----------- ----------- ------- ------------ ----------- ----------- -------
  **Vitamin D metabolism**                                          **276**       245                                  0.580                              0.159                   0.550                    0.160               0.418                    0.116       
  Identified in GWAS of 25(OH)D ^b^                                 2             2                                    0.235               0.759          0.867           0.999   0.167        0.657       0.923       0.990   0.561        0.944       0.499       0.991
  CUBN                                                              116           106                                  0.173               0.741          0.764           0.999   0.130        0.657       0.896       0.990   0.083        0.470       0.490       0.991
  CYP24A1                                                           25            23                                   0.443               0.777          0.358           0.999   0.083        0.647       0.666       0.990   0.622        0.944       **0.007**   0.595
  CYP27A1                                                           5             5                                    0.500               0.777          0.299           0.999   0.488        0.819       0.086       0.522   0.968        0.968       0.256       0.991
  CYP27B1                                                           6             5                                    0.448               0.777          **0.037**       0.446   0.585        0.829       **0.041**   0.448   0.514        0.944       0.154       0.991
  CYP2R1                                                            12            9                                    0.115               0.741          0.811           0.999   0.368        0.815       0.921       0.990   **0.044**    0.459       0.727       0.991
  CYP3A4                                                            7             5                                    0.241               0.759          0.730           0.999   0.461        0.815       0.533       0.990   0.262        0.747       0.392       0.991
  DHCR7                                                             12            6                                    0.997               0.997          0.549           0.999   0.800        0.911       0.614       0.990   0.434        0.944       0.716       0.991
  GC                                                                24            20                                   0.484               0.777          **0.018**       0.406   0.912        0.954       **0.026**   0.442   0.241        0.747       0.316       0.991
  LRP2                                                              67            64                                   0.804               0.926          0.377           0.999   0.508        0.819       0.677       0.990   0.904        0.967       0.487       0.991
  **Mineral homeostasis**                                           58            40                                   0.834                              0.313                   0.912                    0.431               0.537                    0.782       
  CASR                                                              31            23                                   0.580               0.784          0.736           0.999   0.536        0.819       0.957       0.990   0.643        0.944       0.565       0.991
  PTH                                                               6             5                                    0.931               0.982          0.671           0.999   0.773        0.911       0.739       0.990   0.539        0.944       0.736       0.991
  CALB1                                                             2             2                                    0.489               0.777          0.741           0.999   0.400        0.815       0.847       0.990   0.882        0.967       0.819       0.991
  TRPV5                                                             9             7                                    0.657               0.846          0.054           0.456   0.920        0.954       0.081       0.522   0.337        0.818       0.225       0.991
  TRPV6                                                             10            3                                    0.263               0.777          0.880           0.999   0.520        0.819       0.954       0.990   0.112        0.595       0.713       0.991
  **VDR complex/Transcriptional Co-regulators and Co-activators**   538           490                                  0.634                              **0.041**               0.874                    0.105               0.180                    0.727       
  ACTL6A                                                            3             3                                    0.239               0.759          0.395           0.999   0.262        0.815       0.497       0.990   0.506        0.944       0.613       0.991
  ARID1A                                                            8             7                                    0.408               0.777          **0.032**       0.446   0.306        0.815       **0.048**   0.448   0.133        0.628       0.068       0.924
  BAZ1B                                                             14            9                                    0.478               0.777          0.955           0.999   0.360        0.815       0.867       0.990   0.385        0.909       0.935       0.993
  CARM1                                                             4             4                                    0.641               0.839          **0.006**       0.406   0.831        0.929       **0.022**   0.442   0.290        0.747       0.120       0.991
  CHAF1A                                                            5             4                                    **0.035**           0.511          **0.013**       0.406   0.307        0.815       **0.047**   0.448   **0.007**    0.187       0.098       0.926
  CREBBP                                                            15            12                                   0.388               0.777          0.285           0.999   0.800        0.911       0.215       0.865   **0.011**    0.187       0.793       0.991
  EP300                                                             6             5                                    0.771               0.926          0.791           0.999   0.434        0.815       0.835       0.990   0.917        0.967       0.342       0.991
  HDAC9                                                             149           141                                  0.559               0.784          0.873           0.999   0.524        0.819       0.578       0.990   0.553        0.944       0.970       0.993
  MED1                                                              5             5                                    0.507               0.777          0.561           0.999   0.719        0.899       0.694       0.990   0.131        0.628       0.617       0.991
  NCOA1                                                             18            14                                   0.581               0.784          0.065           0.504   0.804        0.911       0.201       0.854   0.239        0.747       0.355       0.991
  NCOA2                                                             19            16                                   0.542               0.781          0.579           0.999   0.145        0.657       0.456       0.990   0.938        0.967       0.505       0.991
  NCOA3                                                             11            9                                    0.067               0.636          0.051           0.456   0.056        0.647       0.069       0.489   0.522        0.944       0.350       0.991
  NCOA7                                                             31            31                                   0.518               0.777          0.142           0.755   0.646        0.872       0.056       0.448   0.223        0.747       0.482       0.991
  NCOR1                                                             7             3                                    0.312               0.777          0.802           0.999   0.377        0.815       0.759       0.990   0.577        0.944       0.489       0.991
  PCAF/KAT2B                                                        31            31                                   0.801               0.926          0.891           0.999   0.470        0.815       0.865       0.990   0.938        0.967       0.797       0.991
  PRMT1                                                             4             4                                    0.346               0.777          0.351           0.999   0.407        0.815       0.184       0.823   0.618        0.944       0.624       0.991
  RXRA                                                              30            27                                   0.683               0.866          0.763           0.999   0.091        0.647       0.732       0.990   0.662        0.944       0.726       0.991
  RXRB                                                              7             3                                    0.824               0.926          0.074           0.526   0.445        0.815       0.058       0.448   0.617        0.944       0.356       0.991
  RXRG                                                              24            24                                   0.853               0.929          0.716           0.999   0.558        0.819       0.923       0.990   0.875        0.967       0.087       0.924
  SMARCA2                                                           1             1                                    0.506               0.777          **0.019**       0.406   0.381        0.815       **0.012**   0.442   0.944        0.967       0.307       0.991
  SMARCA4                                                           12            9                                    0.474               0.777          0.794           0.999   0.559        0.819       0.975       0.990   0.557        0.944       0.923       0.993
  SMARCC1                                                           4             4                                    0.103               0.741          0.893           0.999   0.344        0.815       0.824       0.990   0.082        0.470       0.164       0.991
  SMARCD1                                                           3             3                                    0.312               0.777          0.703           0.999   0.356        0.815       0.550       0.990   0.519        0.944       0.998       0.998
  SMARCE1                                                           4             4                                    **0.048**           0.582          0.197           0.881   0.191        0.706       0.390       0.990   0.083        0.470       0.059       0.924
  SNW1                                                              10            10                                   0.615               0.816          0.863           0.999   0.740        0.911       0.947       0.990   0.813        0.967       0.807       0.991
  SUPT16H                                                           7             6                                    0.809               0.926          0.990           0.999   0.696        0.899       0.960       0.990   0.663        0.944       0.841       0.991
  TOP2B                                                             6             5                                    0.192               0.741          0.965           0.999   0.097        0.647       0.327       0.990   0.281        0.747       0.400       0.991
  NCOR2                                                             62            61                                   0.701               0.877          0.960           0.999   0.770        0.911       0.609       0.990   0.459        0.944       0.935       0.993
  VDR                                                               30            28                                   0.270               0.777          0.652           0.999   0.372        0.815       0.707       0.990   0.477        0.944       0.706       0.991
  TSC2                                                              8             7                                    0.135               0.741          0.885           0.999   0.354        0.815       0.811       0.990   0.284        0.747       0.761       0.991
  **TGF-beta signaling**                                            110           98                                   **0.0001**                         0.616                   **0.0001**               0.729               **0.0001**               0.342       
  RHPN2                                                             25            23                                   0.452               0.777          0.722           0.999   0.144        0.657       0.871       0.990   0.956        0.967       0.701       0.991
  SMAD7                                                             23            18                                   **0.0001**          **0.008**      0.927           0.999   **0.001**    **0.043**   0.947       0.990   **0.0005**   **0.021**   0.627       0.991
  SMAD3                                                             39            38                                   **0.0002**          **0.008**      0.367           0.999   **0.0001**   **0.009**   0.514       0.990   **0.0003**   **0.021**   0.085       0.924
  BMP2                                                              5             5                                    **0.016**           0.346          0.081           0.527   **0.014**    0.298       0.224       0.865   0.072        0.470       **0.049**   0.924
  BMP4                                                              1             1                                    0.201               0.742          0.431           0.999   0.334        0.815       0.615       0.990   0.261        0.747       0.276       0.991
  TGFB1                                                             11            8                                    0.159               0.741          0.293           0.999   0.469        0.815       0.112       0.595   0.068        0.470       0.306       0.991
  TGFBR1                                                            4             3                                    0.950               0.982          0.741           0.999   0.306        0.815       0.838       0.990   0.446        0.944       0.851       0.991
  SCG5/GREM1                                                        2             2                                    0.141               0.741          0.412           0.999   0.170        0.657       0.371       0.990   0.323        0.808       0.656       0.991
  **Inflammation**                                                  133           97                                   0.888                              0.479                   0.620                    0.156               0.200                    0.784       
  ALOX5                                                             22            11                                   0.839               0.926          0.264           0.999   0.801        0.911       0.593       0.990   0.782        0.967       0.165       0.991
  IL10                                                              13            8                                    0.462               0.777          **0.030**       0.446   0.854        0.931       **0.006**   0.442   **0.009**    0.187       0.419       0.991
  IL10R                                                             9             7                                    0.734               0.904          0.552           0.999   0.913        0.954       0.751       0.990   0.663        0.944       0.591       0.991
  IL2/IL21                                                          6             5                                    0.441               0.777          0.933           0.999   0.538        0.819       0.978       0.990   0.666        0.944       0.607       0.991
  IL6                                                               13            10                                   0.983               0.995          0.807           0.999   0.982        0.988       0.557       0.990   0.696        0.967       0.843       0.991
  IL12B                                                             18            17                                   0.128               0.741          0.870           0.999   0.079        0.647       0.796       0.990   0.791        0.967       0.761       0.991
  IFNG                                                              7             4                                    0.300               0.777          0.686           0.999   0.453        0.815       0.608       0.990   0.287        0.747       0.497       0.991
  TNF                                                               4             4                                    0.959               0.982          0.218           0.926   0.988        0.988       0.375       0.990   0.790        0.967       0.076       0.924
  NFKB1                                                             22            15                                   0.816               0.926          0.644           0.999   0.873        0.939       0.736       0.990   0.856        0.967       0.794       0.991
  IL12A                                                             1             1                                    0.523               0.777          0.168           0.795   0.452        0.815       0.159       0.770   0.814        0.967       0.706       0.991
  IL18                                                              4             4                                    0.348               0.777          0.514           0.999   0.613        0.840       0.766       0.990   0.182        0.737       0.290       0.991
  IL1A/IL1B                                                         11            8                                    0.951               0.982          0.124           0.701   0.846        0.931       0.054       0.448   0.761        0.967       0.711       0.991
  IL8                                                               1             1                                    0.153               0.741          0.978           0.999   0.060        0.647       0.593       0.990   0.811        0.967       0.669       0.991
  RELA (p65)                                                        2             2                                    0.921               0.982          0.835           0.999   0.938        0.961       0.962       0.990   0.922        0.967       0.690       0.991
  **Oxidative Stress**                                              51            37                                   0.726                              0.471                   0.598                    0.460               0.913                    0.747       
  GSR                                                               9             7                                    0.530               0.777          0.116           0.701   0.712        0.899       0.110       0.595   0.656        0.944       0.376       0.991
  GPx2                                                              15            8                                    0.834               0.926          0.772           0.999   0.713        0.899       0.748       0.990   0.412        0.944       0.915       0.993
  TXNRD1 (TR1)                                                      17            14                                   0.232               0.759          0.859           0.999   0.168        0.657       0.875       0.990   0.757        0.967       0.946       0.993
  SOD2                                                              10            8                                    0.530               0.777          0.374           0.999   0.546        0.819       0.599       0.990   0.896        0.967       0.281       0.991
  **Insulin growth factor (IGF) signaling**                         61            52                                   0.105                              0.320                   0.550                    0.135               **0.007**                0.346       
  Associated with IGF levels in GWAS ^c^                            4             4                                    0.414               0.777          0.999           0.999   0.579        0.829       0.901       0.990   **0.036**    0.437       0.879       0.993
  IGF1                                                              17            15                                   0.131               0.741          0.452           0.999   0.113        0.657       0.668       0.990   0.225        0.747       0.655       0.991
  IGF2BP2                                                           3             1                                    0.303               0.777          0.923           0.999   0.596        0.830       0.580       0.990   0.156        0.698       0.658       0.991
  IGFBP2/IGFBP5                                                     24            21                                   0.187               0.741          0.052           0.456   0.692        0.899       **0.018**   0.442   **0.029**    0.411       0.607       0.991
  IGFBP3                                                            13            11                                   0.057               0.601          0.882           0.999   0.273        0.815       0.997       0.997   **0.050**    0.459       0.058       0.924
  **Cell Cycle**                                                    60            56                                   0.120                              0.852                   **0.030**                0.845               0.482                    0.916       
  KRAS                                                              13            13                                   0.511               0.777          0.498           0.999   0.262        0.815       0.436       0.990   0.182        0.737       0.925       0.993
  FOS (c-fos)                                                       10            9                                    0.389               0.777          0.425           0.999   0.230        0.815       0.518       0.990   0.764        0.967       0.574       0.991
  JUN                                                               7             7                                    0.569               0.784          0.407           0.999   0.411        0.815       0.163       0.770   0.917        0.967       0.811       0.991
  C-MYC region ^d^                                                  13            13                                   **0.010**           0.295          0.843           0.999   **0.051**    0.647       0.857       0.990   **0.054**    0.459       0.959       0.993
  CCND1                                                             4             3                                    0.177               0.741          0.893           0.999   0.155        0.657       0.565       0.990   0.549        0.944       0.763       0.991
  BCL2A1                                                            2             2                                    0.118               0.741          0.587           0.999   0.083        0.647       0.574       0.990   0.250        0.747       0.915       0.993
  BAX                                                               6             5                                    0.308               0.777          0.892           0.999   0.155        0.657       0.748       0.990   0.922        0.967       0.988       0.998
  CDKN1A                                                            5             4                                    0.521               0.777          0.168           0.795   0.099        0.647       0.459       0.990   0.867        0.967       0.216       0.991
  **VDR binding sites**                                             19            18                                   **0.036**                          0.530                   **0.008**                0.410               0.256                    0.798       
  VDR binding sites ^e^                                             19            18                                   **0.036**           0.511          0.530           0.999   **0.008**    0.227       0.410       0.990   0.256        0.747       0.798       0.991

^a^*P* of false discovery rate (BH; Benjamini--Hochberg or BH) method. ^b^ rs10485165 and rs10507577 (Bejamin et al. 2007) \[[@B27-nutrients-11-01954]\]. ^c^ rs1245541, rs4234798, rs700752, and rs780094. ^d^ Chromosome 8q24 region. ^e^ SNPs located in the *VDR* binding sites relating to colorectal cancer and Crohn's disease risk as previously published (Ramagopalan et al. 2010) \[[@B19-nutrients-11-01954]\].
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###### 

Associations of season-adjusted 25(OH)D concentrations (per 24.96 nmol/L) with CRC risk by genotypes, the EPIC study, 1992--2003.

  Gene/SNP                                                          Major Allele Homozygotes   Heterozygotes      Minor Allele Homozygotes   *P* ~interaction~ ^b^                                 
  ----------------------------------------------------------------- -------------------------- ------------------ -------------------------- ----------------------- --------- ------------------- ----------
  **Vitamin D metabolism**                                                                                                                                                                         
  CYP27B1 rs10877013                                                557/383                    1.00 (0.86,1.17)   510/311                    0.84 (0.73,0.97)        108/70    0.61 (0.40,0.93)    *0.024*
  CYP27B1 rs4646536                                                 551/381                    1.00 (0.86,1.17)   485/300                    0.85 (0.74,0.99)        110/70    0.62 (0.41,0.95)    *0.034*
  GC rs1352846                                                      500/319                    0.96 (0.81,1.13)   406/286                    0.79 (0.67,0.93)        104/68    0.58 (0.35,0.97)    *0.049*
  GC rs16846876                                                     530/331                    1.05 (0.90,1.23)   477/337                    0.75 (0.65,0.88)        144/81    0.88 (0.63,1.21)    *0.017*
  GC rs2298850                                                      584/384                    1.00 (0.86,1.15)   445/293                    0.80 (0.68,0.94)        86/61     0.56 (0.33,0.97)    *0.038*
  GC rs3755967                                                      569/359                    0.99 (0.85,1.15)   436/297                    0.78 (0.66,0.91)        101/64    0.66 (0.40,1.09)    *0.034*
  GC rs842873                                                       261/192                    0.73 (0.58,0.91)   588/354                    0.84 (0.73,0.97)        240/196   1.22 (0.97,1.52)    *0.002*
  **VDR complex/Transcriptional Co-regulators and Co-activators**                                                                                                                                  
  ARID1A rs11247596                                                 720/474                    0.96 (0.85,1.09)   400/256                    0.76 (0.63,0.92)        53/34     0.42 (0.20,0.86)    *0.051*
  ARID1A rs12737946                                                 998/640                    0.83 (0.74,0.93)   168/116                    1.25 (0.95,1.66)        9/8       \- ^c^              *0.016*
  ARID1A rs12752833                                                 998/641                    0.83 (0.74,0.93)   165/114                    1.22 (0.92,1.62)        9/8       \-                  *0.025*
  CARM1 rs7254708                                                   764/515                    0.82 (0.73,0.93)   208/144                    1.04 (0.81,1.32)        9/8       \-                  *0.0001*
  CHAF1A rs243341                                                   596/403                    0.78 (0.68,0.90)   468/276                    0.95 (0.80,1.13)        102/78    1.42 (0.97,2.07)    *0.020*
  CHAF1A rs243365                                                   607/434                    0.80 (0.70,0.91)   408/257                    1.02 (0.86,1.22)        50/44     1.64 (0.89,3.02)    *0.027*
  SMARCA2 rs2296212                                                 920/607                    0.81 (0.72,0.91)   229/142                    1.15 (0.89,1.48)        14/7      4.09 (0.29,58.01)   *0.035*
  **Inflammation**                                                                                                                                                                                 
  IL10 rs3024509                                                    1015/657                   0.92 (0.83,1.03)   132/100                    0.62 (0.45,0.85)        3/2       \-                  *0.024*
  IL10 rs6686931                                                    747/476                    0.80 (0.70,0.91)   373/243                    1.02 (0.86,1.20)        49/38     1.42 (0.59,3.39)    *0.029*

^a^ Adjusted for age at blood collection, sex, and center. ^b^ Interactions between SNPs and 25(OH)D stratifying by categories of 25(OH)D concentrations and assuming a log-additive model for genetic markers. ^c^ Not estimatable due to small sample size.
